Single-nucleus multiomic profiling uncovers epigenetic dysregulation driving hippocampal vulnerability in Alzheimer’s disease
Alzheimer’s disease (AD) exhibits region- and cell-type–specific vulnerability, yet the underlying regulatory mechanisms remain poorly defined. We performed integrated single-nucleus RNA-seq and ATAC-seq of human hippocampus to resolve gene regulatory architecture in AD. By linking chromatin accessibility to transcription, we identified more than 1000 disease-associated cis-regulatory interactions, highlighting coordinated epigenomic-transcriptomic remodeling. Excitatory cornu ammonis (EX.CA) neurons exhibited disproportionate regulatory disruption, characterized by increased chromatin accessibility coupled to activation of apoptosis-related gene programs, whereas dentate gyrus (EX.DG) neurons remained comparatively resistant. In glial cells, regulatory network inference revealed activation of transcription factor modules centered on SPI1/KLF4 in microglia and STAT3 in astrocytes, defining epigenetic programs that are highly associated with inflammatory and metabolic state transitions. Comparative evaluation with the prefrontal cortex uncovered conserved inflammatory activation alongside region-specific immune regulatory divergence, indicating spatially distinct microglial responses. Furthermore, cross-species integration demonstrated that a substantial fraction of AD-associated regulatory elements are human-specific, with AD-risk variants enriched in microglial cis-regulatory elements at loci including BIN1 and APOE . Together, these results provide a mechanistic framework linking chromatin remodeling to cell-type–specific dysfunction and reveal human-specific regulatory architecture as a crucial factor to AD vulnerability and translational limitation.
Authors
- Shiping Liu (ORCID: https://orcid.org/0000-0003-0019-619X)
- Longqi Liu (ORCID: https://orcid.org/0000-0002-5828-5542)
- Quyuan Tao (ORCID: https://orcid.org/0000-0003-2739-3548)
- Yue Gao (ORCID: https://orcid.org/0009-0002-9555-5879)
- Lei Han (ORCID: https://orcid.org/0000-0002-7535-7915)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-7222-8317)
- Ting Luo (ORCID: https://orcid.org/0009-0000-7231-6280)
- Lifang Wang (ORCID: https://orcid.org/0000-0002-6235-3069)
- Bufan Jin
- Zilin Lai
- Langjian Zhu
- Yanrong Wei (ORCID: https://orcid.org/0009-0004-0075-2605)
- Youzhe He (ORCID: https://orcid.org/0009-0004-9534-0303)
- Pan Wang (ORCID: https://orcid.org/0000-0002-6122-5209)
- Heyang Du (ORCID: https://orcid.org/0009-0006-7577-4272)
- Yujie Peng
- Yuyang Liu (ORCID: https://orcid.org/0000-0002-9164-8130)
- Maorui Jiang
- Yong Hou
Institutions
- BGI Group (China) (CN)
- Chinese Academy of Sciences (CN)
- University of Chinese Academy of Sciences (CN)
- First Affiliated Hospital Zhejiang University (CN)
- BGI Research (CN)
- Zhejiang University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Science Advances
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1126/sciadv.aee4760
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China